Artificial Intelligence in Life Sciences Market to Grow at 20% During 2022-2030

Spread the love

According to the report, the global artificial intelligence in life sciences market size is projected to garner $ 6.7 billion by 2030, registering a CAGR of 20% from 2022 to 2030. The report contains 150+ pages with detailed analysis.

Artificial Intelligence in Life Sciences Market Size 2021 to 2030

 

Market Overview

A recent report provides crucial insights along with application based and forecast information in the global artificial intelligence in life sciences market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the artificial intelligence in life sciences market.

The rising technological advances and rapid emergence of the novel technologies like artificial intelligence and its rising applications across various industries has led to the increased demand for the AI in the life sciences industry. The rising need for controlling costs and enhancing the operational efficiencies in the drug discovery and clinical trials is fostering the growth of the AI in life sciences market across the globe.

The rapidly emerging data based AI, technological advances in the deep learning, and growing need for achieving autonomy in robotics are expected to boost the demand for the AI technology in the life sciences industry. The inefficiency of the drug discovery process due to factors such as high costs of research and development, low success rate in clinical trials, and growing focus on rare diseases is fueling the adoption of the AI in life sciences to improve efficiency and reduce costs. The machine learning technology can enhances the candidate recruitment functions, data, storage, and data analytics, which is anticipated to fuel the market growth during the forecast period.

Download the Sample Pages of this Report for Better Understanding (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1776

The main objective of this research report is to define and describe the market and offer a complete valuation of the market revenue/volume with the help of widespread quantitative and qualitative insights, and forecasts of the market. This report presents a breakdown of the market into forthcoming and niche segments. Additionally, this research study gauges market revenue growth and its drift at global, regional, and country from 2022 to 2030.

This research report evaluates the artificial intelligence in life sciences market on a global and regional level. It offers a thorough analysis of the market status, growth, and forecast of the global artificial intelligence in life sciences market for the period from 2017 to 2030. This research study offers historic data for the years 2017 to 2020 along with a forecast from 2022 to 2030 based on value.

Report Scope of the Artificial Intelligence (AI) in Life Sciences Market

Report Coverage Details
Market Size by 2030 USD 6.7 Billion
Growth Rate from 2022 to 2030 CAGR of 20%
Largest Market North America
Fastest Growing Region Europe
Base Year 2021
Forecast Period 2022 to 2030
Segments Covered Offering, Deployment, Application, Geography

Report Highlights

  • By offering, the software segment dominated the market, owing to the rising adoption of the software among the life science companies. This is attributed to the rising importance and need for data collection, processing, management, and analytics. The software can offer various benefits related to the data.
  • By deployment, the cloud segment dominated the market. The rising penetration of internet and rising advances in the IT and telecommunications industry has led to the development of advanced cloud based servers that can improve the operations of the organization as per their requirements and can easily store, manage, and share data.
  • Based on application, the drug discovery segment dominated the market owing to the rising adoption of Ai in the drug discovery process. The AI can efficiently control costs and improve the operational efficiency in the drug discovery activities.

Regional Snapshot

North America led the global AI in life sciences market. US was the major driver of the North America AI in life sciences market in 2021. The US is known to be the home of the several leading biotech and pharma companies that are the major investors in the research and development, drug discovery, and clinical trial activities. The increased demand for the AI technology among the research organizations and the pharmaceutical companies has led to the dominance of North America in the AI in life sciences market. Approximately US$80 billion was invested on research and development by the pharmaceutical companies in 2018 across the globe, as per the data of Pharmaceutical Research and Manufacturers of America (PhRMA). US leads the globe in terms of new drug discovery and development and it holds the property rights of the majority of the drugs that has been recently developed.

Asia Pacific is the home to several top research organizations that are the major drivers of the AI in life sciences market in Asia Pacific. The presence of top research institutions and rising investments in the research studies of various diseases and its treatment has bolstered the demand for the AI hardware and software in Asia Pacific region. The growing government investments towards advancing the medical infrastructure and rising pharma FDIs in the region is expected to boost the growth of the market in the forthcoming years.

Market Dynamics

Driver

Growing need for clinical trials and drug discovery

Drug discovery and clinical trials are expensive affairs that involve huge recurring costs. The research, development, candidate recruitment, candidate retention, and various phases of clinical trials, each of them are very costly and the low success rate of these activities increases the costs for the company at a significant level. As per the Pharmaceutical Research and Manufacturers of America (PhRMA), the pharma companies spends around 19 % of their revenue, on an average, in the research. Therefore, the growing the growing need for controlling costs and improving outcomes is boosting the adoption of AI in life sciences field.

Restraints

Huge capital investments

The artificial intelligence is an expensive and latest technology that has gained a rapid traction across the globe and across various industry verticals. The rising need for data analytics, deep learning, machine learning, and natural language processing are the major drivers of the AI technology. However, the high capital investments in the deployment of AI in the life sciences companies may hinder the market growth during the forecast period.

Opportunity

Lack of AI experts

AI is a new technology and there is a dearth of experts and skilled staffs that can efficiently handle the AI based software and hardware systems. This automatically increases the third party services provided by the AI in life sciences market players, which increases the revenues of the AI in life sciences market players. This factor is offering the market players to generate huge revenues on recurring basis.

Challenge

Data privacy and cybersecurity

With the growing adoption of the digital technologies, the risks of malware and cyberattacks has significantly increased across the globe. The growing number of cyberattacks and rising concerns regarding the data privacy is the major challenge for the market players.

Get Our Latest Press Releases@ https://www.precedenceresearch.com/press-releases

Recent Developments

  • In June 2020, The University of Kentucky andAtomwise, entered into a strategic collaboration for small molecule discovery, to discover potential therapies for COVID-19.

Top Key Players includes in the artificial intelligence in life sciences market:

  • IBM Corporation
  • Atomwise, Inc.
  • Nuance Communications, Inc.
  • NuMedii, Inc.
  • AiCure LLC.
  • APIXIO, Inc.
  • Insilico Medicine, Inc.
  • Enlitic, Inc.
  • Sensely, Inc.
  • Zebra Medical Vision

Segments Covered in the Report

By Offering

  • Software
  • Hardware
  • Services

By Deployment

  • On Premise
  • Cloud

By Application

  • Medical Diagnosis
  • Drug Discovery
  • Precision and Personalized Medicine
  • Biotechnology
  • Clinical Trials
  • Patient Monitoring

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Why should you invest in this report?

If you are aiming to enter the global artificial intelligence in life sciences market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for artificial intelligence in life sciences are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Artificial Intelligence (AI) in Life Sciences Market 

5.1. COVID-19 Landscape: Artificial Intelligence (AI) in Life Sciences Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Artificial Intelligence (AI) in Life Sciences Market, By Offering

8.1. Artificial Intelligence (AI) in Life Sciences Market, by Offering, 2022-2030

8.1.1Software

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Hardware

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Services

8.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Artificial Intelligence (AI) in Life Sciences Market, By Deployment

9.1. Artificial Intelligence (AI) in Life Sciences Market, by Deployment, 2022-2030

9.1.1. On Premise

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Cloud

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Artificial Intelligence (AI) in Life Sciences Market, By Application 

10.1. Artificial Intelligence (AI) in Life Sciences Market, by Application, 2022-2030

10.1.1. Medical Diagnosis

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Drug Discovery

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Precision and Personalized Medicine

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Biotechnology

10.1.4.1. Market Revenue and Forecast (2017-2030)

10.1.5. Clinical Trials

10.1.5.1. Market Revenue and Forecast (2017-2030)

10.1.6. Patient Monitoring

10.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Artificial Intelligence (AI) in Life Sciences Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Offering (2017-2030)

11.1.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.1.3. Market Revenue and Forecast, by Application (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Offering (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.1.4.3. Market Revenue and Forecast, by Application (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Offering (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.1.5.3. Market Revenue and Forecast, by Application (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Offering (2017-2030)

11.2.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.2.3. Market Revenue and Forecast, by Application (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Offering (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.2.4.3. Market Revenue and Forecast, by Application (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Offering (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.2.5.3. Market Revenue and Forecast, by Application (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Offering (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.2.6.3. Market Revenue and Forecast, by Application (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Offering (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.2.7.3. Market Revenue and Forecast, by Application (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Offering (2017-2030)

11.3.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.3.3. Market Revenue and Forecast, by Application (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Offering (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.3.4.3. Market Revenue and Forecast, by Application (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Offering (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.3.5.3. Market Revenue and Forecast, by Application (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Offering (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.3.6.3. Market Revenue and Forecast, by Application (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Offering (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.3.7.3. Market Revenue and Forecast, by Application (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Offering (2017-2030)

11.4.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.4.3. Market Revenue and Forecast, by Application (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Offering (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.4.4.3. Market Revenue and Forecast, by Application (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Offering (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.4.5.3. Market Revenue and Forecast, by Application (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Offering (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.4.6.3. Market Revenue and Forecast, by Application (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Offering (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.4.7.3. Market Revenue and Forecast, by Application (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Offering (2017-2030)

11.5.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.5.3. Market Revenue and Forecast, by Application (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Offering (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.5.4.3. Market Revenue and Forecast, by Application (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Offering (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Deployment (2017-2030)

11.5.5.3. Market Revenue and Forecast, by Application (2017-2030)

Chapter 12. Company Profiles

12.1.IBM Corporation

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Atomwise, Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Nuance Communications, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. NuMedii, Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. AiCure LLC.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. APIXIO, Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Insilico Medicine, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Enlitic, Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Sensely, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Zebra Medical Vision

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1776

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: [email protected]


Spread the love

About Top PR News

TopPRnews Leads Drives Search Engine Visibility For Your Press Release Content. Our Global Network Reaches Important Contacts, Media Partners And Websites And Journalists. Happy Postings! If You Have Any Queries Please Contact Official Mail At [[email protected]}

View all posts by Top PR News →